Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N.
Siddiqui BA, et al. Among authors: tannir n.
J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850.
J Immunother Cancer. 2021.
PMID: 34326169
Free PMC article.